DLBCL
MCID: DFF005
MIFTS: 55

Diffuse Large B-Cell Lymphoma (DLBCL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Diffuse Large B-Cell Lymphoma

MalaCards integrated aliases for Diffuse Large B-Cell Lymphoma:

Name: Diffuse Large B-Cell Lymphoma 12 52 58 15 37 17 71 32
Dlbcl 52 58
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified 71
Large B-Cell Diffuse Lymphoma 74

Characteristics:

Orphanet epidemiological data:

58
diffuse large b-cell lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (France); Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0050745
ICD10 32 C83.3
MESH via Orphanet 44 D016403
ICD10 via Orphanet 33 C83.3
UMLS via Orphanet 72 C0079744
Orphanet 58 ORPHA544
UMLS 71 C0079744 C2699777

Summaries for Diffuse Large B-Cell Lymphoma

NIH Rare Diseases : 52 Diffuse large B-cell lymphoma (DLBCL), a form of non-Hodgkin lymphoma, is the most common blood cancer . Lymphomas occur when cells of the immune system , known as B lymphocytes , grow and multiply uncontrollably. DLBCL occurs mostly in adults and is a fast-growing (aggressive) lymphoma. It can start in the lymph nodes or outside of the lymphatic system in the gastrointestinal tract, testes , thyroid, skin, breast, bone, or brain. Often, the first sign of DLBCL is a painless rapid swelling in the neck, armpit, abdomen, or groin caused by enlarged lymph nodes. For some people, the swelling may be painful. Other symptoms include night sweats, unexplained fevers, and weight loss. Treatment may differ depending on the location of the tumor and the subtype of lymphoma. For those who have advanced DCBCL and have not been treated previously, a combination of chemotherapy and the monoclonal antibody rituximab (Rituxan) (R-CHOP ) may be tried. . In addition, as of October 2017, axicabtagene ciloleucel (brand name: Yescarta), a type of gene therapy , has been approved by the United States FDA to treat DCBCL that is not responding to at least two treatment attempts or has returned after being treated before. A stem cell transplant may also be an option if DLBCL returns or relapses.

MalaCards based summary : Diffuse Large B-Cell Lymphoma, also known as dlbcl, is related to b-cell lymphoma and follicular lymphoma. An important gene associated with Diffuse Large B-Cell Lymphoma is MIR155 (MicroRNA 155), and among its related pathways/superpathways are MicroRNAs in cancer and Alzheimers Disease. The drugs Epirubicin and Vindesine have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone.

Disease Ontology : 12 A B-cell lymphoma that is a cancer of B cells presenting as an aggressive tumour which can arise in virtually any part of the body.

Wikipedia : 74 Diffuse large B-cell lymphoma (DLBCL) is a cancer of B cells, a type of lymphocyte that is responsible... more...

Related Diseases for Diffuse Large B-Cell Lymphoma

Diseases related to Diffuse Large B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 830)
# Related Disease Score Top Affiliating Genes
1 b-cell lymphoma 33.5 MIR21 MIR17HG MIR17 MIR155 HOTAIR
2 follicular lymphoma 33.3 MIR210 MIR17 MIR155
3 burkitt lymphoma 31.6 MIR21 MIR17HG MIR155 MIR150 MIR145 MIR143
4 leukemia, chronic lymphocytic 31.2 PEG10 MIR21 MIR17HG MIR17 MIR155 MIR150
5 dermatomyositis 30.9 MIR210 MIR21 MIR155
6 leukemia, acute myeloid 30.8 MIR210 MIR21 MIR17 MIR155 MIR150 MIR145
7 nasopharyngeal carcinoma 30.8 MIR21 MIR17 MIR143 HULC HOTAIR
8 leiomyoma, uterine 30.8 MIR21 MIR150 MIR10A
9 polymyositis 30.7 MIR210 MIR21 MIR155 MIR127
10 rectum cancer 30.5 MIR21 MIR17 MIR150 MIR145 MIR143
11 gallbladder disease 30.5 MIR17 MIR145 MIR143
12 glioma 30.5 MIR210 MIR21 MIR17 HULC HOTAIR
13 central nervous system disease 30.3 MIR210 MIR21 MIR17 MIR155 MIR150 MIR145
14 heart disease 30.3 MIR210 MIR21 MIR17 MIR155 MIR145 HOTAIR
15 brain cancer 30.3 MIR21 MIR17 MIR155 MIR150 MIR145 MIR10A
16 esophageal cancer 30.2 PEG10 MIR21 MIR155 MIR145 MIR143 HULC
17 nervous system disease 30.2 MIR210 MIR21 MIR17 MIR155 MIR150 MIR145
18 lymphatic system cancer 30.1 MIR21 MIR17 MIR155 MIR150 MIR145 MIR143
19 intestinal disease 30.1 MIR21 MIR17 MIR155 MIR150 MIR145 MIR143
20 bladder cancer 30.0 PANDAR MIR21 MIR17 MIR145 MIR143 MIR127
21 gastric cancer 30.0 PANDAR MIR21 MIR17 MIR155 MIR150 MIR145
22 connective tissue disease 29.9 MIR210 MIR21 MIR17 MIR155 MIR150 MIR145
23 renal cell carcinoma, nonpapillary 29.9 PANDAR MIR210 MIR21 MIR17 MIR155 MIR150
24 arteries, anomalies of 29.8 MIR210 MIR21 MIR17 MIR155 MIR150 MIR145
25 gastrointestinal system disease 29.8 MIR210 MIR21 MIR17 MIR155 MIR150 MIR145
26 ovarian cancer 29.0 MIR210 MIR21 MIR17 MIR155 MIR150 MIR145
27 relapsed/refractory diffuse large b-cell lymphoma 13.0
28 primary cutaneous diffuse large b-cell lymphoma, leg type 13.0
29 epstein-barr virus-positive diffuse large b-cell lymphoma of the elderly 12.9
30 diffuse large b-cell lymphoma of the central nervous system 12.9
31 diffuse large b-cell lymphoma with chronic inflammation 12.9
32 gray zone lymphoma 12.4
33 primary central nervous system lymphoma 12.3
34 plasmablastic lymphoma 12.1
35 t-cell/histiocyte rich large b cell lymphoma 12.1
36 reticulosarcoma 12.0
37 primary mediastinal b-cell lymphoma 11.9
38 richter's syndrome 11.9
39 mediastinal gray zone lymphoma 11.7
40 lymphoma 11.6
41 primary mediastinal large b-cell lymphoma 11.4
42 intravascular large b-cell lymphoma 11.3
43 lymphoma, hodgkin, classic 11.3
44 lymphoma, non-hodgkin, familial 11.3
45 alk-positive large b-cell lymphoma 11.2
46 neutropenia 11.0
47 mantle cell lymphoma 10.9
48 lymphoma, mucosa-associated lymphoid type 10.9
49 central nervous system lymphoma 10.8
50 marginal zone b-cell lymphoma 10.8

Graphical network of the top 20 diseases related to Diffuse Large B-Cell Lymphoma:



Diseases related to Diffuse Large B-Cell Lymphoma

Symptoms & Phenotypes for Diffuse Large B-Cell Lymphoma

Drugs & Therapeutics for Diffuse Large B-Cell Lymphoma

Drugs for Diffuse Large B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 307)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 4 56420-45-2 41867
2
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
3 Endothelial Growth Factors Phase 4
4
Apatinib Phase 4 811803-05-1
5
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
6
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
7
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
8
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
9
Vinblastine Approved Phase 3 865-21-4 241903 13342
10
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
11
Iodine Approved, Investigational Phase 3 7553-56-2 807
12
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
13
Venetoclax Approved, Investigational Phase 2, Phase 3 1257044-40-8 49846579
14
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
15
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
16
Rasburicase Approved, Investigational Phase 2, Phase 3 134774-45-1
17
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
18
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
19
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
20
rituximab Approved Phase 3 174722-31-7 10201696
21
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
22
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
23
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
24
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
25
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
26
Bevacizumab Approved, Investigational Phase 3 216974-75-3
27
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
28
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
29
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 5280795 6221
30
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
31 Molgramostim Investigational Phase 3 99283-10-0
32 Hormones Phase 3
33 Antineoplastic Agents, Hormonal Phase 3
34 glucocorticoids Phase 3
35 Hormone Antagonists Phase 3
36 Alkylating Agents Phase 3
37 Immunosuppressive Agents Phase 3
38 Anti-Bacterial Agents Phase 3
39 Immunologic Factors Phase 3
40 Antibiotics, Antitubercular Phase 3
41 Antirheumatic Agents Phase 3
42 Anti-Inflammatory Agents Phase 3
43 Epoetin alfa Phase 3 113427-24-0
44 Interleukin-2 Phase 3
45 cadexomer iodine Phase 3
46 Iodine-131 anti-B1 antibody Phase 3
47 Hematinics Phase 2, Phase 3
48 Nitrogen Mustard Compounds Phase 3
49 Antidotes Phase 2, Phase 3
50 Antineoplastic Agents, Immunological Phase 3

Interventional clinical trials:

(show top 50) (show all 962)
# Name Status NCT ID Phase Drugs
1 A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
2 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Unknown status NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
3 Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study Completed NCT03376958 Phase 4 Apatinib
4 LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
5 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Completed NCT01990534 Phase 4 Brentuximab vedotin
6 Four Cycles of R-CHOP Followed by Four Cycles of Rituximab Versus Six Cycles of R-CHOP Followed by Two Cycles of Rituximab in the Treatment of de Novo, Low-risk, Non-bulky Diffuse Large B-cell Lymphoma. Recruiting NCT02752815 Phase 4 Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
7 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03579082 Phase 4 Decitabine
8 Lenalidomide, Rituximab and Combination Chemotherapy Versus Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Highly Aggressive Non-Hodgkin B-cell Lymphoma Recruiting NCT04152577 Phase 4 R2-combination chemotherapy;R-combination chemotherapy
9 Study Evaluating Relapses in Central Nervous System in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy With or Without CNS Prophylaxis. Multicentric, Prospective, Randomized Phase III Study Unknown status NCT02777736 Phase 3 Methotrexate
10 A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B Unknown status NCT01852435 Phase 3 R-CEOP-70;R-CEOP-90;R-CHOP-50
11 R-CHOP Therapy Compared With R-CHOP Plus Biocell Natural Killer Mixture in Patients With DLBCL (Diffuse Large B Cell Lymphoma);A Randomized, Open-label,Multi-center Trail Unknown status NCT00846157 Phase 3
12 Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Randomised, Multicentre, Non-inferiority Study Unknown status NCT02428751 Phase 3 Pegylated liposomal doxorubicin;Doxorubicin;Rituximab;Cyclophophamide;Vincristine;Prednisone
13 Busulfan+ Cyclophosphamide+ Etoposide vs Busulfan+ Cyclophosphamide Conditioning Regimen for Diffuse Large B-cell Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03229616 Phase 2, Phase 3 Busulfan (BU);Cyclophosphamide (CY);Etoposide (VP-16)
14 A Multicenter, Randomized, Double-blind, Controlled, Phase III Study to Evaluate the Efficacy and Safety of IBI301 (Recombinant Chimeric Anti-CD20 Monoclonal Antibody ) in Combination With CHOP Regimen Versus Rituximab in Combination With CHOP Regimen in Treatment-naïve Patients With Diffuse Large B-cell Lymphoma (DLBCL) Unknown status NCT02867566 Phase 3 IBI301 plus CHOP;Rituximab plus CHOP
15 A Phase Ⅲ, Multi-center, Randomized, Controlled Study to Compare the Efficiency and Safety of SCT400(Recombinant Chimeric Anti-CD20 Monoclonal Antibody, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated CD20-positive DLBCL Patients Unknown status NCT02772822 Phase 3 SCT400 plus CHOP;Rituximab plus CHOP
16 A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma Unknown status NCT03151044 Phase 3 High-dose Epirubicin Combined with CVP ± Rituximab;Standard-dose Epirubicin Combined with CVP ± Rituximab
17 Phase 3 Study of 30Gy Versus 40Gy Involved-field Radiotherapy in Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
18 Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients Unknown status NCT01277172 Phase 2, Phase 3
19 A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells. Unknown status NCT00499018 Phase 3 Rituximab;Ciclofosfamide;Doxorubicina;Vincristina;Prednisone;Pegfilgrastim;Mitoxantrone;ARA-C;Lenograstim;BCNU;ARA-C;VP-16;Ciclofosfamide;Doxorubicina;Vincristina
20 Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
21 A Phase III, Open-Label, Prospective, Two-Armed, Multicenter, Randomized, Group Sequential Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study Regimen Versus Observation in Patients With Diffuse Large B-Cell Lymphoma Who Are in Complete Remission After First-Line CHOP-Rituximab (CHOP-R) Therapy Unknown status NCT00322218 Phase 3 Zevalin Therapeutic Regimen
22 High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial Unknown status NCT02531841 Phase 3 Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
23 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
24 A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant Completed NCT01321541 Phase 3 Pixantrone + Rituximab;Gemcitabine + Rituximab
25 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib Completed NCT01324596 Phase 3 Intravenous;Bortezomib
26 Prospective Study of ACVBP Followed by Autologous Stem Cell Transplantation in Case of BCL-2 Overexpression in Non Previously Treated Patients Aged 60 Years or Less With Low-Intermediate Risk Diffuse Large B-Cell Lymphoma Completed NCT00169130 Phase 2, Phase 3 doxorubicin;cyclophosphamide
27 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Completed NCT01855750 Phase 3 Ibrutinib;Placebo;Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone (or equivalent)
28 A Randomized, Open-label, Mutli-centre Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2, OR 3A Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
29 A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
30 Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1. Completed NCT00140595 Phase 3 rituximab;doxorubicin;cyclophosphamide
31 A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT01148446 Phase 3 Cyclophosphamide;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Prednisone;Epirubicin;Vinblastine;Rituximab;G-CSF
32 Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-cell Lymphoma. Completed NCT00144755 Phase 3 Darbepoetin alfa
33 PHASE 1B/PHASE 3 MULTICENTER STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION REGIMENS THAT INCLUDE AN IMMUNE AGONIST, EPIGENETIC MODULATOR, CD20 ANTAGONIST AND/OR CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) JAVELIN DLBCL Completed NCT02951156 Phase 3 Bendamustine;Gemcitabine;Oxaliplatin
34 A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin Completed NCT00332202 Phase 3 enzastaurin;placebo
35 Open Label, Single-arm, Phase IIIb Clinical Trial to Evaluate the Safety of Switching From Intravenous Rituximab to Subcutaneous Rituximab During First Line Treatment for CD20+ Non-Hodgkin's Follicular Lymphoma and Diffuse Large B-cell Lymphoma. Completed NCT01987505 Phase 3 Rituximab
36 A Comparative, Randomized, Parallel-group, Multi-center, Phase IIIB Study to Investigate the Efficacy of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL) Completed NCT01649856 Phase 3 CHOP;rituximab [MabThera/Rituxan];rituximab [MabThera/Rituxan]
37 An Open-labeled, Multi-center, Randomized, Prospective Phase III Study Comparing CMAB304 in Combination With CHOP to CHOP Alone With CMAB304 Maintenance in Patients With DLBCL Completed NCT01459887 Phase 3 CHOP combined with CMAB304;CHOP, CMAB304
38 A Phase 2/3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid ®) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Completed NCT01197560 Phase 2, Phase 3 Lenalidomide;Gemcitabine;Oxaliplatin;Rituximab;Etoposide
39 A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy Versus a Reference Rituximab Plus CHOP (R-CHOP) in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Given as First Line Completed NCT02268045 Phase 3
40 Multicentric Randomized Phase III Study Comparing High Doses of Chemotherapy With Rituximab Followed by Auto-transplant HPC Versus CHOP Plus Rituximab as First Line Therapy in High Risk Patients With DLBCL Non-Hodgkin's Lymphomas Completed NCT00355199 Phase 3 Rituximab-HDS;Rituximab-CHOP
41 Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab Completed NCT00137995 Phase 3 Rituximab;Etoposide;Carboplatine;Ifosfamide + Mesna;Cisplatine;Cytosine Arabinoside;Dexamethasone;BCNU;Etoposide;Cytarabine;Melphalan
42 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3 Rituximab
43 A Single Arm, Multicentre, Phase IIIB Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Completed NCT01889069 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Doxorubicin;Prednisone;Bendamustine
44 Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas Completed NCT00118209 Phase 3 cyclophosphamide;doxorubicin;vincristine;prednisone;etoposide;filgrastim;pegfilgrastim
45 Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line Completed NCT01122472 Phase 3 Lenalidomide;Placebo
46 A Phase III Multicenter, Open-label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma Completed NCT00719472 Phase 3 Rituximab;CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone);CVP (cyclophosphamide, vincristine, prednisone);Analgesic/antipyretic and antihistamine drugs
47 Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant (ASCT) in Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT01014208 Phase 3 OFATUMUMAB + DHAP;RITUXIMAB + DHAP
48 Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma Completed NCT02617485 Phase 3 Rituximab;Doxorubicin;Vincristine;Cyclophosphamide;prednisone
49 SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma Completed NCT00491491 Phase 3 ibritumomab tiuxetan
50 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide

Search NIH Clinical Center for Diffuse Large B-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diffuse Large B-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Diffuse Large B-Cell Lymphoma

Anatomical Context for Diffuse Large B-Cell Lymphoma

MalaCards organs/tissues related to Diffuse Large B-Cell Lymphoma:

40
B Cells, T Cells, Bone, Bone Marrow, Breast, Thyroid, Liver

Publications for Diffuse Large B-Cell Lymphoma

Articles related to Diffuse Large B-Cell Lymphoma:

(show top 50) (show all 12861)
# Title Authors PMID Year
1
Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. 61 46
19287466 2009
2
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. 46 61
18537969 2008
3
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. 61 46
18318758 2008
4
MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. 61 46
17487835 2007
5
BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. 61 46
16041695 2005
6
Accumulation of miR-155 and BIC RNA in human B cell lymphomas. 46 61
15738415 2005
7
Downregulation of microRNAs-143 and -145 in B-cell malignancies. 46
17892514 2007
8
MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. 46
16675453 2006
9
Chemoimmunotherapy for localised low-risk diffuse large B-cell lymphoma. 61
31868615 2020
10
A multicentre retrospective study of primary breast diffuse large B-cell and high-grade B-cell lymphoma treatment strategies and survival. 61
32476626 2020
11
Prognostic significance of Twist, ZEB1 and Slug in peripheral T-cell lymphomas. 61
32567520 2020
12
Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens. 61
32311849 2020
13
Primary bone lymphoma of the thoracic vertebra in a patient with metastatic lung cancer. 61
32438255 2020
14
Lymphoproliferative tumors involving the lacrimal drainage system: a major review. 61
31267826 2020
15
Risk of mature B-cell neoplasms and precursor conditions after joint replacement: A report from the Haematological Malignancy Research Network. 61
31675431 2020
16
Diffuse large B-cell lymphoma presenting with cavitary lung disease. 61
32405417 2020
17
Comprehensive characterization of driver genes in diffuse large B cell lymphoma. 61
32565964 2020
18
Posttreatment FDG-Avid Splenic Lesions in DLBCL and HD: Clinical and Radiographic Characteristics for Risk Assessment. 61
32433173 2020
19
Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse. 61
31768966 2020
20
CAR-T Treatment: Determining the Survival Gain in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma. 61
32173272 2020
21
Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma. 61
32180274 2020
22
Effectiveness of digital PCR for MYD88L265P detection in vitreous fluid for primary central nervous system lymphoma diagnosis. 61
32536998 2020
23
A presentation, treatment, and survival analysis of primary cardiac lymphoma cases reported from 2009 to 2019. 61
32285360 2020
24
Progressive multifocal leukoencephalopathy after CAR T therapy. 61
32125605 2020
25
A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. 61
32171691 2020
26
Primary effusion lymphoma metachronous to multicentric Castleman disease in an immunocompetent patient. 61
32534717 2020
27
Gain-of-function mutations in CARD11 promote enhanced aggregation and idiosyncratic signalosome assembly. 61
32473470 2020
28
Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. 61
31973908 2020
29
Clinical manifestations of oral lymphomas - Retrospective study of 15 cases in a Taiwanese population and a review of 592 cases from the literature. 61
32505589 2020
30
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. 61
32141616 2020
31
EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice. 61
32542010 2020
32
Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas. 61
32483241 2020
33
Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades. 61
32281275 2020
34
Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma. 61
32497402 2020
35
[Clinical Characteristics of 219 Patients with Primary Gastrointestinal Non-Hodgkin's Lymphoma]. 61
32552946 2020
36
Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: A Case Report. 61
32566435 2020
37
TBLR1 and CREBBP as potential novel prognostic immunohistochemical biomarkers in diffuse large B-cell lymphoma. 61
32546039 2020
38
Impact on survival through consolidation radiotherapy for diffuse large B-cell lymphoma: a comprehensive meta-analysis. 61
32554560 2020
39
Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma. 61
32273479 2020
40
Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. 61
32500753 2020
41
Mutational landscape of immune surveillance genes in diffuse large B-cell lymphoma. 61
32293210 2020
42
Impact of HIV infection on consolidative radiotherapy for non-Hodgkin diffuse large B-cell lymphoma. 61
32539797 2020
43
Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab? 61
32558356 2020
44
Diffuse Large B-cell Lymphoma Responds to Tafasitamab plus Lenalidomide. 61
32561557 2020
45
Gastric emphysema in chemosensitive gastric diffuse large B cell lymphoma. 61
32519093 2020
46
Diffuse large B-cell lymphoma with low 18F-fluorodeoxyglucose avidity features silent B-cell receptor signaling. 61
32090646 2020
47
Hypercalcemia as Initial Manifestation of Primary Splenic Diffuse Large B-Cell Lymphoma. 61
32505555 2020
48
Paraneoplastic Cerebellar Degeneration in Diffuse Large B-cell Lymphoma and Review of Associated Onconeural Antibodies. 61
32171690 2020
49
Syndrome of inappropriate antidiuretic hormone secretion in a patient with diffuse large B-cell lymphoma. 61
31627961 2020
50
Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study. 61
32043382 2020

Variations for Diffuse Large B-Cell Lymphoma

Cosmic variations for Diffuse Large B-Cell Lymphoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM93183630 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.743G>A p.R248Q 17:7674220-7674220 0

Copy number variations for Diffuse Large B-Cell Lymphoma from CNVD:

7 (show top 50) (show all 118)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13828 1 1 84900000 Loss Diffuse large b-cell lymphoma
2 17406 1 142600000 249250621 Gain Diffuse large b-cell lymphoma
3 20082 1 15300000 163800000 Gain Diffuse large b-cell lymphoma
4 38345 10 101900000 103000000 Gain Diffuse large b-cell lymphoma
5 38773 10 104900000 105800000 Gain Diffuse large b-cell lymphoma
6 38901 10 105800000 121700000 Loss Diffuse large b-cell lymphoma
7 40597 10 130600000 135534747 Loss Diffuse large b-cell lymphoma
8 43294 10 46100000 64500000 Loss Diffuse large b-cell lymphoma
9 48479 11 1 43500000 Gain Diffuse large b-cell lymphoma
10 51204 11 123900000 135006516 Loss Diffuse large b-cell lymphoma
11 53206 11 26100000 36400000 Loss Diffuse large b-cell lymphoma
12 55792 11 55700000 135006516 Gain Diffuse large b-cell lymphoma
13 64291 12 12600000 14800000 Gain CDKN1B Diffuse large b-cell lymphoma
14 70914 12 66000000 69800000 Gain MDM2 Diffuse large b-cell lymphoma
15 74343 13 104800000 110300000 Loss Diffuse large b-cell lymphoma
16 74383 13 105800000 109100000 Loss Diffuse large b-cell lymphoma
17 75387 13 19500000 55300000 Gain Diffuse large b-cell lymphoma
18 76712 13 35500000 75400000 Loss Diffuse large b-cell lymphoma
19 79280 13 68600000 115169878 Gain Diffuse large b-cell lymphoma
20 86223 14 55800000 61200000 Loss Diffuse large b-cell lymphoma
21 88116 14 84900000 107349540 Loss Diffuse large b-cell lymphoma
22 90236 15 20700000 102531392 Loss Diffuse large b-cell lymphoma
23 97251 16 1 34600000 Gain Diffuse large b-cell lymphoma
24 97373 16 1 7900000 Gain ABCA3 Diffuse large b-cell lymphoma
25 97375 16 1 7900000 Gain DCI Diffuse large b-cell lymphoma
26 97377 16 1 7900000 Gain E4F1 Diffuse large b-cell lymphoma
27 97379 16 1 7900000 Gain HAGH Diffuse large b-cell lymphoma
28 97381 16 1 7900000 Gain IGFALS Diffuse large b-cell lymphoma
29 97383 16 1 7900000 Gain MRPS34 Diffuse large b-cell lymphoma
30 97385 16 1 7900000 Gain NME3 Diffuse large b-cell lymphoma
31 97387 16 1 7900000 Gain NUBP2 Diffuse large b-cell lymphoma
32 97391 16 1 7900000 Gain RNPS1 Diffuse large b-cell lymphoma
33 99692 16 28100000 36600000 Loss Diffuse large b-cell lymphoma
34 102840 16 57400000 90354753 Gain Diffuse large b-cell lymphoma
35 102843 16 57400000 90354753 Loss Diffuse large b-cell lymphoma
36 104071 16 66700000 70800000 Gain DDX19 Diffuse large b-cell lymphoma
37 104073 16 66700000 70800000 Gain FUK Diffuse large b-cell lymphoma
38 104075 16 66700000 70800000 Gain SIAT4B Diffuse large b-cell lymphoma
39 106530 16 88700000 90354753 Gain Diffuse large b-cell lymphoma
40 106806 17 1 22200000 Loss Diffuse large b-cell lymphoma
41 111431 17 3600000 6800000 Loss TP53 Diffuse large b-cell lymphoma
42 120634 18 2900000 78077248 Gain Diffuse large b-cell lymphoma
43 121454 18 43500000 48200000 Gain Diffuse large b-cell lymphoma
44 121719 18 46400000 52000000 Gain BCL2 Diffuse large b-cell lymphoma
45 122173 18 53800000 56200000 Gain MALT1 Diffuse large b-cell lymphoma
46 123098 18 66800000 68700000 Loss Diffuse large b-cell lymphoma
47 123108 18 66900000 71300000 Gain Diffuse large b-cell lymphoma
48 127687 19 35500000 38300000 Gain KIRREL2 Diffuse large b-cell lymphoma
49 127689 19 35500000 38300000 Gain MLL4 Diffuse large b-cell lymphoma
50 127691 19 35500000 38300000 Gain NPHS1 Diffuse large b-cell lymphoma

Expression for Diffuse Large B-Cell Lymphoma

Search GEO for disease gene expression data for Diffuse Large B-Cell Lymphoma.

Pathways for Diffuse Large B-Cell Lymphoma

Pathways related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.72 MIR210 MIR21 MIR17 MIR155 MIR150 MIR145
2 11.51 MIR21 MIR127 MIR10A
3 11.18 MIR17HG MIR17 MIR127 MIR10A

GO Terms for Diffuse Large B-Cell Lymphoma

Cellular components related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 MIR210 MIR21 MIR17 MIR155 MIR150 MIR143

Biological processes related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of angiogenesis GO:0016525 9.67 MIR10A MIR143 MIR145 MIR21
2 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.61 MIR21 MIR143
3 positive regulation of cardiac muscle hypertrophy GO:0010613 9.61 MIR21 MIR155
4 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.6 MIR21 MIR10A
5 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.59 MIR21 MIR17
6 positive regulation of macrophage activation GO:0043032 9.58 MIR155 MIR145
7 negative regulation of cardiac muscle hypertrophy GO:0010614 9.58 MIR21 MIR145
8 regulation of smooth muscle contraction GO:0006940 9.57 MIR145 MIR143
9 negative regulation of innate immune response GO:0045824 9.56 MIR21 MIR155
10 positive regulation of endothelial cell differentiation GO:0045603 9.55 MIR21 MIR150
11 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.54 MIR17 MIR155
12 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.52 MIR17 MIR155
13 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.51 MIR17 MIR155
14 positive regulation of metalloendopeptidase activity GO:1904685 9.49 MIR21 MIR17
15 angiotensin-activated signaling pathway GO:0038166 9.48 MIR145 MIR143
16 negative regulation of regulatory T cell differentiation GO:0045590 9.46 MIR21 MIR155
17 aorta smooth muscle tissue morphogenesis GO:0060414 9.43 MIR143 MIR145
18 regulation of phenotypic switching GO:1900239 9.4 MIR143 MIR145
19 miRNA mediated inhibition of translation GO:0035278 9.35 MIR145 MIR155 MIR17 MIR21 MIR210
20 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.33 MIR17 MIR21 MIR210
21 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.32 MIR143 MIR17
22 gene silencing by miRNA GO:0035195 9.32 MIR10A MIR127 MIR143 MIR145 MIR150 MIR155
23 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.26 MIR143 MIR145

Molecular functions related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.28 MIR210 MIR21 MIR17HG MIR17 MIR155 MIR150

Sources for Diffuse Large B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....